The global pharmaceutical industry is rapidly reorganizing its structure by switching from synthetic drugs to biomedicine such as antibodies and vaccines. In Korea, a new market for biosimilar and stem cell medicine and the existing market is preparing for the development of the biomedicine industry.

Unlike chemically synthesized pharmaceuticals, criteria for the biopharmaceuticals are established in accordance with their biological characteristics rather than physiochemical ones and some countries are involved in direct management of the quality control for such products to make approvals.

We have sufficient experts and high-tech equipment meeting the criteria for paradigm changes to the pharmaceutical industry and physiochemical characteristics.